Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B

Clin Microbiol Infect. 2012 Feb;18(2):E24-6. doi: 10.1111/j.1469-0691.2011.03714.x. Epub 2011 Nov 30.

Abstract

We used molecular techniques to analyse 87 (n = 70 patients) Aspergillus terreus complex isolates, all of which were identified as A. terreus sensu stricto. The antifungal susceptibilities determined with CLSI M38-A2 (and Etest for amphotericin B) and expressed as mg/L for range of MIC/MIC(90) /geometric mean were as follows: itraconazole, 0.25-2/2/1.097; voriconazole, 0.125-2/2/1.176; posaconazole, 0.25-1/1/0.836; amphotericin B CLSI, 4-32/16/9.689; and Etest, 0.75-64/6/3.106. The MICs for amphotericin B were significantly higher than those found for the triazoles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / pharmacology*
  • Antifungal Agents / pharmacology*
  • Aspergillosis / microbiology*
  • Aspergillus / classification*
  • Aspergillus / drug effects*
  • Aspergillus / genetics
  • Aspergillus / isolation & purification
  • Azoles / pharmacology*
  • Cluster Analysis
  • DNA, Fungal / chemistry
  • DNA, Fungal / genetics
  • DNA, Ribosomal / chemistry
  • DNA, Ribosomal / genetics
  • DNA, Ribosomal Spacer / chemistry
  • DNA, Ribosomal Spacer / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Mycology / methods
  • Phylogeny
  • RNA, Ribosomal, 5.8S / genetics
  • Sequence Analysis, DNA

Substances

  • Antifungal Agents
  • Azoles
  • DNA, Fungal
  • DNA, Ribosomal
  • DNA, Ribosomal Spacer
  • RNA, Ribosomal, 5.8S
  • Amphotericin B